Open Angle Glaucoma Market

DelveInsight’s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast—2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber.


The current treatment management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Open-angle glaucoma – Disease Understanding and Treatment Algorithm

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases.


OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of OAG are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

Open-angle glaucoma – Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.


As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. DelveInsight’s analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this, it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG.

Open-angle glaucoma – Drug Chapters

This segment of the Open-angle glaucoma (OAG) report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


The treatment and market of OAG are dependent on the class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP – 716 (Sun Pharma), Trabodenoson (Inotek Pharmaceuticals), DE-30A (Santen), and others.


Prostaglandin derivatives, beta-blockers, Topical carbonic anhydrase inhibitors (CAIs), alpha2-adrenergic receptor agonists and Combination therapies are the most preferred classes for the treatment of open-angle glaucoma. In the United States, drugs of this class have been approved in the past few years like Vyzulta, Xelpros, Travatan Z, and a few others by the US FDA. Rhopressa which is marketed in both the US and Europe (Rhokiinsa), has recently completed the phase II trial in Japan. The company is looking to meet with Japan’s Pharmaceutical and Medical Devices Agency to discuss these results and identify the next steps for a phase III program in Japan. Apart from this, Ube Industries and Santen Pharmaceutical in Japan developed a famous ophthalmic product known as Omidenepag isopropyl ophthalmic solution 0.002 %, which is marketed under the name of EYBELIS is a selective prostaglandin E2 receptor 2 agonist with a non-prostaglandin structure for the treatment of glaucoma and ocular hypertension.


There are several unmet needs in the management of Glaucoma and to meet these unmet needs, various pharmaceutical companies have started working toward the development of the novel product for this indication. Pharmaceutical companies, like Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia S.A de C.V., Nicox Ophthalmics, and Nicox Ophthalmics developing products that have the potential to change the open-angle glaucoma treatment landscape.


Allergan’s drug candidate, Bimatoprost SR is a biodegradable sustained-release implant, which is currently under development in phase III for the treatment of OAG and ocular hypertension. The solid, rod-shaped implant consists of the prostaglandin analog (PGA) bimatoprost within the company’s Novadur platform for drug delivery. In July 2019, the United States Food and Drug Administration (US FDA) accepted Allergan's new drug application for bimatoprost sustained-release in patients with OAG or ocular hypertension. The FDA is expected to take action on the NDA by the end of the first half of 2020.


PDP – 716 is the once-a-day formulation of Brimonidine developed using SPARC’s TearActTM Technology for treatment of Glaucoma by Sun Pharma. PDP – 716 provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. SPARC initiated the pivotal Phase III study for PDP – 716 in the USA. The study is randomizing patients and is expected to be completed by Q4 FY 2020. SPARC is in discussion with potential partners for licensing of PDP – 716.


Among all these mentioned companies Santen is constantly working to meet the unmet needs of the OAG. Two of its products are in pipeline (phase II and Phase III), i.e., DE-130A and Sepetaprost (ONO-9054). DE-130A is an ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension. This product is in phase III clinical development stage. Santen recently initiated the phase III trial in Europe and Asia and planning to complete it in 2021. On the other hand, ONO-9054 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). ONO-9054 is expected to show a superior intraocular pressure (IOP) lowering effect compared to FP receptor agonists.


The company has completed the Phase II clinical trial of ONO-9054 for the treatment of glaucoma and ocular hypertension in the US. In the future, Santen will seek manufacturing and marketing approval for ONO-9054 on a worldwide basis. There are several other products in the clinical development for the treatment of OAG.

Open-angle glaucoma – Market Outlook

The Open-angle glaucoma (OAG) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.


As per the assessment by DelveInsight’s analysts, it has been observed that the market size of OAG was observed to be USD 3,316.71 million in 2017, in the 7MM. Among all the seven major markets, the United States covers the major market share that accounts for 41.01% of the 7MM. In 2017, the market size was accessed to be USD 1,360.30 million in the country.


The products which are anticipated to be launched in the 7MM include Bimatoprost SR (Sustained-Release; Allergan), DE-117 (omidenepag isopropyl; Santen Pharmaceutical); PRO-122 (Laboratorios Sophia); PDP – 716 (Brimonidine; Sun Pharma); Sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics) and Nyxol (Phentolamine Mesylate: Ocuphire Pharma). However, in addition to this, it is anticipated that Aerie Pharma with its two products ROCKLATAN and RHOPRESSA/Rhokiinsa will definitely show an impact on the open-angle glaucoma market of Europe. Recently, in November 2019, the European Commission (EC) granted marketing authorization to Rhokiinsa 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.


Besides this Sun Pharma Advanced Research Company (SPARC) is also expecting the launch of its product PDP – 716 (Brimonidine). In addition to this, a product named), DE-130A (of Santen Pharmaceutical is also anticipated to be launched in the European countries. ROCKLATAN and RHOPRESSA are approved in the US and recently Aerie pharma received a positive opinion from the CHMP. This positive opinion will help in the smooth launch of RHOPRESSA (under the name RHOKIINSA).


Some of these products have completed the late clinical stages of development, while others are in ongoing late clinical development stages. These drug candidates have shown very promising results and it has been anticipated by DelveInsight’s analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of OAG will have better management practices.

Open-angle glaucoma (OAG) – Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.


The current therapeutic landscape of advanced stage OAG in the 7MM is driven by several approved therapies, including those with generic products. Of this, majority of the market share is accommodated by Prostaglandin analogs generating USD 1,806.12 million, followed by Carbonic anhydrase inhibitors generating USD 578.42 million while Miotics contributed the least towards the market share, with USD 146.31 million.


To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of OAG during our forecast period, including In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP – 716 (Sun Pharma.), DE-130A (Santen), and others.

Open-angle glaucoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Open-angle glaucoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Countries Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Open-angle glaucoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Open-angle glaucoma market
  • Organize sales and marketing efforts by identifying the best opportunities for Open-angle glaucoma market
  • To understand the future market competition in the Open-angle glaucoma market.



What is Open-Angle Glaucoma?

Open-Angle Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of open-angle glaucoma. It develops slowly and sometimes without noticeable sight loss for many years.


What was the market size of Open-Angle Glaucoma in 2017?

Open-Angle Glaucoma Market Size in the 7MM was found to be USD 3,316.71 million in 2017.


What are the Open-Angle Glaucoma market drivers?

Rich Emerging Pipeline, Development of Advanced Antiglaucoma Medications, Patient-Friendly Dosage Regimes, Rise in Awareness, and Development of Treatment Methods to Tackle the Situation of Non-Adherence are the Open-Angle Glaucoma market drivers.


What are the Open-Angle Glaucoma market barriers?

Lack of animal models, Socioeconomic Barriers, and Lack of Patient Pool due to under-diagnosis are the Open-Angle Glaucoma market barriers.



Which companies are developing drugs for Open-Angle Glaucoma?

Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia S.A de C.V., Nicox Ophthalmics, and Nicox Ophthalmics are developing drugs for Open-Angle Glaucoma.

1.       Key Insights

2.       Executive Summary of Open-Angle Glaucoma

3.       Open-Angle Glaucoma (OAG): Market Overview at a Glance

3.1.     Total Market Share (%) Distribution of OAG in 2017

3.2.     Total Market Share (%) Distribution of OAG in 2030

4.       Open-Angle Glaucoma: Disease Background and Overview

4.1.     Introduction

4.2.     Classification of Open-Angle Glaucoma

4.3.     Signs and Symptoms of Open-Angle Glaucoma

4.4.     Risk Factors of Primary Open-Angle Glaucoma (POAG)

4.4.1.   General

4.4.2.   Ocular

4.4.3.   Nonocular

4.4.4.   Ocular Hypertension

4.5.     Pathophysiology of Primary Open-Angle Glaucoma (POAG)

4.6.     Genes Involved in Primary Open-Angle Glaucoma

4.6.1.   Myocilin

4.6.2.   Optineurin

4.6.3.   TANK-binding Kinase-1 (TBK1)

4.6.4.   WD-repeat domain 36 (WDR36, OMIM 609669)

4.7.     Biomarkers associated with Primary Open Angle Glaucoma (POAG)

4.8.     Diagnosis of Open-Angle Glaucoma

4.8.1.   Diagnosis of Primary Open-Angle Glaucoma

4.8.2.   Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

5.       Case Reports

5.1.     Managing Juvenile Open-Angle Glaucoma

5.2.     Visual improvement following glaucoma surgery: a case report

5.3.     Evidence-based medicine in glaucoma surgery

6.       Epidemiology and Patient Population

6.1.     Key Findings

6.2.     Epidemiology and Market Methodology

6.3.     Total Prevalence of Glaucoma in the 7MM

6.4.     Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM

6.5.     Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM

7.       United States Epidemiology

7.1.     Assumptions and Rationale

7.2.     Total Prevalence of Glaucoma in the United States

7.3.     Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States

7.4.     Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

7.5.     Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

7.6.     Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8.       EU5 Epidemiology

8.1.     Germany Epidemiology

8.1.1.   Assumptions and Rationale

8.1.2.   Total Prevalence of Glaucoma in Germany

8.1.3.   Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany

8.1.4.   Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany

8.1.5.   Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany

8.1.6.   Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany

8.2.     France Epidemiology

8.2.1.   Assumptions and rationale

8.2.2.   Total Prevalence of Glaucoma in France

8.2.3.   Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France

8.2.4.   Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France

8.2.5.   Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France

8.2.6.   Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France

8.3.     Italy Epidemiology

8.3.1.   Assumptions and Rationale

8.3.2.   Total Prevalence of Glaucoma in Italy

8.3.3.   Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy

8.3.4.   Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy

8.3.5.   Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy

8.3.6.   Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy

8.4.     Spain Epidemiology

8.4.1.   Assumptions and Rationale

8.4.2.   Total Prevalence of Glaucoma in Spain

8.4.3.   Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain

8.4.4.   Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain

8.4.5.   Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain

8.4.6.   Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain

8.5.     United Kingdom Epidemiology

8.5.1.   Assumptions and Rationale

8.5.2.   Total Prevalence of Glaucoma in the United Kingdom

8.5.3.   Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom

8.5.4.   Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

8.5.5.   Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

8.5.6.   Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

9.       Japan Epidemiology

9.1.     Assumptions and Rationale

9.2.     Total Prevalence of Glaucoma in Japan

9.3.     Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan

9.4.     Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

9.5.     Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

9.6.     Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

10.    Treatment Algorithm, Current Treatment, and Medical Practices

10.1.  Treatment Algorithm for Open-Angle Glaucoma

10.2.  Treatment and Management for Open-Angle Glaucoma

10.2.1. Basis for Treatment

10.2.2. Available Treatment Options

10.2.3. Medical (Pharmaceutical) Treatment

10.2.4. Laser Trabeculoplasty

10.2.5. Surgery

10.3.  Treatment Guidelines

10.3.1. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

10.3.2. European Glaucoma Society Terminology and Guidelines for Glaucoma

10.4.  Prognosis and Follow-up of Open-Angle Glaucoma

10.4.1. Prognosis

10.4.2. Frequency of Follow-up

10.4.3. Therapy Modification

10.4.4. Effectiveness of Treatment

10.5.  Management of Patients with Severe, Irreversible Vision Loss

11.    Unmet Needs

12.    Marketed Products

12.1.  Marketed Products And Their Relative Therapeutic Classes

12.2.  Rocklatan: Aerie Pharmaceuticals

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.4. Safety and efficacy

12.2.5. Adverse Reaction

12.2.6. Product Profile

12.3.  Rhopressa: Aerie Pharmaceuticals

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.4. Safety and efficacy

12.3.5. Product Profile

12.4.  XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited

12.4.1. Product Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.4. Product Profile

12.5.  EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.4. Safety and efficacy

12.5.5. Product Profile

12.6.  VYZULTA: Bausch and Lomb

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Clinical Development

12.6.4. Safety and efficacy

12.6.5. Product Profile

12.7.  TAPCOM/ DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Clinical Development

12.7.4. Product Profile

12.8.  GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa LTD.

12.8.1. Product Description

12.8.2. Regulatory Milestones

12.8.3. Clinical Development

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9.  Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research

12.9.1. Product Description

12.9.2. Regulatory Milestones

12.9.3. Clinical Development

12.9.4. Safety and efficacy

12.9.5. Product Profile

12.10.                    ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.

12.10.1.    Product Description

12.10.2.    Regulatory Milestones

12.10.3.    Clinical Development

12.10.4.    Safety and efficacy

12.10.5.    Product Profile

12.11.                    DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research

12.11.1.    Product Description

12.11.2.    Regulatory Milestones

12.11.3.    Clinical Development

12.11.4.    Safety and efficacy

12.11.5.    Product Profile

12.12.                    TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company

12.12.1.    Product Description

12.12.2.    Regulatory Milestones

12.12.3.    Clinical Development

12.12.4.    Safety and efficacy

12.12.5.    Product Profile

12.13.                    LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan

12.13.1.    Product Description

12.13.2.    Regulatory Milestones

12.13.3.    Clinical Development

12.13.4.    Product Profile

13.    Emerging Therapies

13.1.  Key Cross Competition

13.2.  Bimatoprost SR (Sustained-Release): Allergan

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Safety and Efficacy

13.2.5. Product Profile

13.3.  PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Safety and Efficacy

13.3.5. Product Profile

13.4.  PRO-122: Laboratorios Sophia S.A de C.V.

13.4.1. Product Description

13.4.2. Clinical Development

13.4.3. Safety and Efficacy

13.4.4. Product Profile

13.5.  Brinzolamide Ophthalmic Suspension 1%: Perrigo Company

13.5.1. Product Description

13.5.2. Clinical Development

13.5.3. Product Profile

13.6.  DE-130A (latanoprost): Santen Pharmaceutical

13.6.1. Product Description

13.6.2. Clinical Development

13.6.3. Product Profile

13.7.  CKD-351: Chong Kun Dang Pharmaceutical

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Product Profile

13.8.  Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical

13.8.1. Product Description

13.8.2. Other Development Activities

13.8.3. Clinical Development

13.8.4. Product Profile

13.9.  NCX 470: Nicox Ophthalmics

13.9.1. Product Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.9.4. Product Profile

13.10.                    Bamosiran (SYL040012): Sylentis

13.10.1.    Product Description

13.10.2.    Other Developmental Activities

13.10.3.    Clinical Development

13.10.4.    Product Profile

13.11.                    ENV515 (Travoprost XR): Envisia Therapeutics

13.11.1.    Product Description

13.11.2.    Other Developmental Activities

13.11.3.    Clinical Development

13.11.4.    Product Profile

13.12.                    Nyxol (Phentolamine Mesylate): Ocuphire Pharma

13.12.1.    Product Description

13.12.2.    Other Developmental Activities

13.12.3.    Clinical Development

13.12.4.    Product Profile

13.13.                    POLAT-001: Peregrine Ophthalmic

13.13.1.    Product Description

13.13.2.    Other Developmental Activities

13.13.3.    Clinical Development

13.13.4.    Product Profile

14.    Failed Therapies

14.1.  Trabodenoson: Inotek Pharmaceuticals

14.1.1. Product Description

14.1.2. Other Developmental Activities

14.1.3. Clinical Development

14.1.4. Safety and Efficacy

14.1.5. Product Profile

14.2.  OTX-TP (Travoprost): Ocular Therapeutix

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.2.4. Product Profile

15.    Open-Angle Glaucoma (OAG): 7MM Market Analysis

15.1.  Key Findings

15.2.  Market Size of Open-Angle Glaucoma in 7MM

15.3.  Market Size of Open-Angle Glaucoma by Therapies in the 7MM

16.    United States: Market Outlook

16.1.  United States Market Size

16.1.1. Total Market size of Open-Angle Glaucoma in the United States

16.1.2. Market Size of Open-Angle Glaucoma by Therapies in the US

17.    EU-5 countries: Market Outlook

17.1.  Germany Market Size

17.1.1. Total Market size of Open-Angle Glaucoma in Germany

17.1.2. Market Size of Open-Angle Glaucoma by therapies in Germany

17.2.  France Market Size

17.2.1. Total Market size of Open-Angle Glaucoma in France

17.2.2. Market Size of Open-Angle Glaucoma by therapies in France

17.3.  Italy Market Size

17.3.1. Total Market size of Open-Angle Glaucoma in Italy

17.3.2. Market Size of Open-Angle Glaucoma by therapies in Italy

17.4.  Spain Market Size

17.4.1. Total Market size of Open-Angle Glaucoma in Spain

17.4.2. Market Size of Open-Angle Glaucoma by therapies in Spain

17.5.  United Kingdom Market Size

17.5.1. Total Market size of Open-Angle Glaucoma in the United Kingdom

17.5.2. Market Size of Open-Angle Glaucoma by therapies in the UK

18.    Japan Market Outlook

18.1.  Japan Market Size

18.1.1. Total Market size of Open-Angle Glaucoma in Japan

18.1.2. Market Size of Open-Angle Glaucoma by therapies in Japan

19.    Access and Reimbursement Overview of Open-Angle Glaucoma

20.    Market Drivers

21.    Market Barriers

22.    SWOT Analysis

23.    Appendix

23.1.  Report Methodology

24.    DelveInsight Capabilities

25.    Disclaimer

26.    About DelveInsight

Table 1: Summary of OAG Market, Epidemiology, and Key Events (2017–2030)

Table 2: Clinical Stages of Primary Open-Angle Glaucoma

Table 3: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations

Table 4: Genes associated with the risk of POAG

Table 5: Innate and adaptive immunity changes in POAG

Table 6: The definitions and levels of evidence to rate individual studies

Table 7: Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE

Table 8: Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

Table 9: Total Prevalence of Glaucoma in the 7MM (2017–2030)

Table 10: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017–2030)

Table 11: Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017–2030)

Table 12: Total Prevalence of Glaucoma in the United States (2017–2030)

Table 13: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017–2030)

Table 14: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017–2030)

Table 15: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States(2017–2030)

Table 16: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017–2030)

Table 17: Total Prevalence of Glaucoma in Germany (2017–2030)

Table 18: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017–2030)

Table 19: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017–2030)

Table 20: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017–2030)

Table 21: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017–2030)

Table 22: Total Prevalence of Glaucoma in France (2017–2030)

Table 23: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017–2030)

Table 24: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017–2030)

Table 25: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017–2030)

Table 26: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017–2030)

Table 27: Total Prevalence of Glaucoma in Italy (2017–2030)

Table 28: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017–2030)

Table 29: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017–2030)

Table 30: Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017–2030)

Table 31: Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017–2030)

Table 32: Total Prevalence of Glaucoma in Spain (2017–2030)

Table 33: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017–2030)

Table 34: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017–2030)

Table 35: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017–2030)

Table 36: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017–2030)

Table 37: Total Prevalence of Glaucoma in the United Kingdom (2017–2030)

Table 38: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom (2017–2030)

Table 39: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017–2030)

Table 40: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017–2030)

Table 41: Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017–2030)

Table 42: Total Prevalence of Glaucoma in Japan (2017–2030)

Table 43: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017–2030)

Table 44: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017–2030)

Table 45: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017–2030)

Table 46: Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017–2030)

Table 47: Suggestions for the Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension

Table 48: Pharmacological Agents for Management of Primary Open-Angle Glaucoma

Table 49: General Guidelines for Postoperative Management of Patients Following Argon Laser Trabeculoplasty

Table 50: European Glaucoma Society Terminology and Guidelines for Glaucoma

Table 51: List of Marketed Drugs and their Relative Therapeutic Classes

Table 52: Rocklatan, Clinical Trial Description, 2020

Table 53: Rhopressa, Clinical Trial Description, 2020

Table 54: EYBELIS Ophthalmic Solution 0.002%, Clinical Trial Description, 2020

Table 55: Vyzulta, Clinical Trial Description, 2020

Table 56: DE-111; Clinical Trial Description, 2020

Table 57: Glanatec, Clinical Trial Description, 2020

Table 58: Simbrinza, Clinical Trial Description, 2020

Table 59: Zioptan, Clinical Trial Description, 2020

Table 60: DuoTrav, Clinical Trial Description, 2020

Table 61: TRAVATAN Z, Clinical Trial Description, 2020

Table 62: Lumigan 0.01%, Clinical Trial Description, 2020

Table 63: Emerging Keycross Competition

Table 64: Bimatoprost SR (Sustained-Release) Clinical Trial Description, 2020

Table 65: PDP – 716, Clinical Trial Description, 2020

Table 66: PRO-122, Clinical Trial Description, 2020

Table 67: Brinzolamide Ophthalmic Suspension 1%, Clinical Trial Description, 2020

Table 68: DE-130A (latanoprost), Clinical Trial Description, 2020

Table 69: CKD-351, Clinical Trial Description, 2020

Table 70: DE-126, Clinical Trial Description, 2020

Table 71: NCX 470, Clinical Trial Description, 2020

Table 72: SYL040012 (bamosiran) , Clinical Trial Description, 2020

Table 73: ENV515 Travoprost XR, Clinical Trial Description, 2020

Table 74: Nyxol (Phentolamine Mesylate), Clinical Trial Description, 2020

Table 75: POLAT-001, Clinical Trial Description, 2020

Table 76: Trabodenoson (INO-8875), Clinical Trial Description, 2020

Table 77: OTX-TP (Travoprost), Clinical Trial Description, 2020

Table 78: Market Size of Open-Angle Glaucoma in 7MM in USD Million (2017–2030)

Table 79: Market Size of Open-Angle Glaucoma by therapies in the 7MM, in USD Million (2017–2030)

Table 80: Currently Prescribed Classes and their Side-Effects

Table 81: The US Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 82: Market Size of Open-Angle Glaucoma by therapies in the US, in USD Million (2017–2030)

Table 83: Germany Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 84: Market Size of Open-Angle Glaucoma by therapies in Germany, in USD Million (2017–2030)

Table 85: France Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 86: Market Size of Open-Angle Glaucoma by therapies in France, in USD Million (2017–2030)

Table 87: Italy Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 88: Market Size of Open-Angle Glaucoma by therapies in Italy, in USD Million (2017–2030)

Table 89: Spain Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 90: Market Size of Open-Angle Glaucoma by therapies in Spain, in USD Million (2017–2030)

Table 91: The UK Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 92: Market Size of Open-Angle Glaucoma by therapies in the UK, in USD Million (2017–2030)

Table 93: Japan Market Size of Open-Angle Glaucoma in USD Million (2017–2030)

Table 94: Market Size of Open-Angle Glaucoma by therapies in Japan, in USD Million (2017–2030)

Figure 1: Aqueous humor production and flow

Figure 2: Development of Glaucoma

Figure 3: Classification of Open-Angle Glaucoma

Figure 4: Symptoms of Open-Angle Glaucoma

Figure 5 :Risk Factors Associated with POAG

Figure 6: Factors Contributing to the Pathophysiology of Glaucomatous Neurodegeneration

Figure 7: Pathophysiology of Primary Open-Angle Glaucoma

Figure 8: Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by a MYOC mutation

Figure 9: Diagnosis of Primary Open-Angle Glaucoma (POAG)

Figure 10: Glaucoma Assessment (Optic Nerve)

Figure 11: Total Prevalence of Glaucoma in the 7MM (2017–2030)

Figure 12: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017–2030)

Figure 13: Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017–2030)

Figure 14: Total Prevalence of Glaucoma in the United States (2017–2030)

Figure 15: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017–2030)

Figure 16: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017–2030)

Figure 17: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017–2030)

Figure 18: Type-Specific Diagnosed Prevalence of OAG in the United States (2017–2030)

Figure 19: Total Prevalence of Glaucoma in Germany (2017–2030)

Figure 20: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017–2030)

Figure 21: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017–2030)

Figure 22: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017–2030)

Figure 23: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017–2030)

Figure 24: Total Prevalence of Glaucoma in France (2017–2030)

Figure 25: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017–2030)

Figure 26: Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017–2030)

Figure 27: Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017–2030)

Figure 28: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017–2030)

Figure 29: Total Prevalence of Glaucoma in Italy (2017–2030)

Figure 30: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017–2030)

Figure 31: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017–2030)

Figure 32: Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017–2030)

Figure 33: Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017–2030)

Figure 34: Total Prevalence of Glaucoma in Spain (2017–2030)

Figure 35: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017–2030)

Figure 36: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017–2030)

Figure 37: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017–2030)

Figure 38: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017–2030)

Figure 39: Total Prevalence of Glaucoma in the United Kingdom (2017–2030)

Figure 40: Total Diagnosed Prevalent Population of OAG in the United Kingdom (2017–2030)

Figure 41: Gender-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017–2030)

Figure 42: Age-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017–2030)

Figure 43: Type-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017–2030)

Figure 44: Total Prevalence of Glaucoma in Japan (2017–2030)

Figure 45: Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017–2030)

Figure 46: Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017–2030)

Figure 47: Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017–2030)

Figure 48: Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017–2030)

Figure 49: Treatment of primary open-angle glaucoma: Medical treatment

Figure 50: Treatment Algorithm for Open-Angle Glaucoma

Figure 51: Unmet Needs of Open-Angle Glaucoma

Figure 52: Factors which can influence Patients Quality of Life (QoL)

Figure 53: Market Size of Open-Angle Glaucoma in the 7MM in USD Million (2017–2030)

Figure 54: Market Size of Open-Angle Glaucoma by therapies in the 7MM, in USD Million (2017–2030)

Figure 55: Market Size of Open-Angle Glaucoma in the US, USD Millions (2017–2030)

Figure 56: Market Size of Open-Angle Glaucoma by therapies in the United States, in USD Million (2017–2030)

Figure 57: Market Size of Open-Angle Glaucoma in Germany, USD Millions (2017–2030)

Figure 58: Market Size of Open-Angle Glaucoma by therapies in Germany, in USD Million (2017–2030)

Figure 59: Market Size of Open-Angle Glaucoma in France, USD Millions (2017–2030)

Figure 60: Market Size of Open-Angle Glaucoma by therapies in France, in USD Million (2017–2030)

Figure 61: Market Size of Open-Angle Glaucoma in Italy, USD Millions (2017–2030)

Figure 62: Market Size of Open-Angle Glaucoma by therapies in Italy in USD Million (2017–2030)

Figure 63: Market Size of Open-Angle Glaucoma in Spain, USD Millions (2017–2030)

Figure 64: Market Size of Open-Angle Glaucoma by therapies in Spain in USD Million (2017–2030)

Figure 65: Market Size of Open-Angle Glaucoma in the UK, USD Millions (2017–2030)

Figure 66: Market Size of Open-Angle Glaucoma by therapies in the UK in USD Million (2017–2030)

Figure 67: Market Size of Open-Angle Glaucoma in Japan, USD Millions (2017–2030)

Figure 68: Market Size of Open-Angle Glaucoma by therapies in Japan in USD Million (2017–2030)

Figure 69: Market Drivers

Figure 70: Market Barriers

Figure 71: SWOT analysis

  • Tags:
  • Open-Angle Glaucoma market
  • Open-Angle Glaucoma market research
  • Open-Angle Glaucoma market insight
  • Open-Angle Glaucoma market trends
  • Open-Angle Glaucoma market forecast
  • Open-Angle Glaucoma market share
  • Open-Angle Glaucoma pipeline drugs
  • Open-Angle Glaucoma treatment algor...
  • Open-Angle Glaucoma drugs
  • Open-Angle Glaucoma sales forecasti...
  • Open-Angle Glaucoma market size
  • Open-Angle Glaucoma disease
  • Open-Angle Glaucoma epidemiology
  • Open-Angle Glaucoma

Forward to Friend

Need A Quote